NASDAQ:ONCY Oncolytics Biotech Q4 2025 Earnings Report $0.67 +0.01 (+1.73%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$0.69 +0.01 (+2.00%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-$0.08Consensus EPS -$0.06Beat/MissMissed by -$0.02One Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETUpcoming EarningsOncolytics Biotech's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Oncolytics Biotech Earnings HeadlinesOncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma1 hour ago | rttnews.comOncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to ImmunotherapySeptember 29 at 9:30 AM | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.September 30 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)September 28 at 12:44 AM | theglobeandmail.comOncolytics Nears Interim Data Update From Randomized REO 033 Colorectal Cancer StudySeptember 28 at 2:43 PM | rttnews.comOncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal CancerSeptember 28 at 9:51 AM | quiverquant.comQSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (NASDAQ:ONCY) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational form of reovirus designed to selectively target certain cancer cells and stimulate an immune response against tumors. Oncolytics is evaluating pelareorep in combination with other cancer treatments, including immune checkpoint inhibitors and chemotherapy. Its research has focused primarily on breast cancer, pancreatic cancer and other solid tumors, with development programs conducted through collaborations and clinical studies in North America and other regions. Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics Biotech operates as a development-stage biotechnology company. Pelareorep has not been approved for commercial sale, and the company’s programs remain subject to clinical, regulatory and other development requirements.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
